Ketoconazole therapy for advanced prostate cancer.
Fifteen patients with biopsy-proven prostate cancer were treated with ketoconazole 400 mg every 8 h. Two patients withdrew from therapy, one for personal reasons and one because a paraspinal mass developed. The other thirteen patients completed at least 6 months of therapy. Ketoconazole greatly reduced the need for analgesics; serum prostatic acid phosphatase levels fell to normal, and testosterone levels were reduced. After 6 months thirteen of fourteen evaluable patients were in remission. The side-effects of ketoconazole therapy were limited.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D000135:Acid Phosphatase; D007654:Ketoconazole